RxDoctor Payments Data

Floyd Shurley, MD

Family Medicine · Cabot, ARNPI 1972509040

Payments from drug & device makers

$1,144in general payments, 2019–2025

Across 60 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$304
  • AstraZeneca$267
  • Lilly USA, LLC$142
  • Currax Pharmaceuticals LLC$96
  • Novo Nordisk$62
  • Pfizer$53
  • plus $221 from 9 others

What the payments were for

  • Food & beverage$1,09496%
  • Education$504%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,144 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$19,538
Medicare patients
142
Services billed
1,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate46$38,685
FarxigaDapagliflozin Propanediol31$23,899
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$11,998
JardianceEmpagliflozin11$10,769
EliquisApixaban13$9,487
Rosuvastatin Calcium287$3,941
Verapamil SrVerapamil Hcl22$2,490
Candesartan Cilexetil20$2,009
SynthroidLevothyroxine Sodium17$1,512
Nebivolol Hcl31$1,430
Metformin Hcl ErMetformin Hcl117$1,266
Gabapentin68$1,064
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,057
Diclofenac Sodium ErDiclofenac Sodium17$1,019
Esomeprazole Magnesium38$995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$33$38,68546 claims
AstraZenecaFarxiga$267$23,89931 claims
Boehringer IngelheimJardiance$11$10,76911 claims
PfizerEliquis$53$9,48713 claims
AbbVieSynthroid$304$1,51217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Cabot

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →